loader from loading.io
πŸ₯ƒ Small Sip, Big Risk: Rethinking Alcohol & Health show art πŸ₯ƒ Small Sip, Big Risk: Rethinking Alcohol & Health

Dr. Baliga's 'Podkasts for Curious Docs'

🚨 New insights from Annals of Internal Medicine challenge long-held beliefs about alcohol 🍷 and health 🧬. A 2025 U.S. Surgeon General advisory links even modest drinking to increased cancer risk πŸŽ—οΈβ€”especially breast and oral cancers. Experts now urge clearer labeling, better patient counseling 🩺, and culturally normalizing abstinence 🌱. Is it time to rethink the β€œglass of red wine” advice? 🧐 #PublicHealth #AlcoholAwareness #PreventiveMedicine #AnnalsOfIM

info_outline
Renal Nerves πŸ”₯ Blood Pressure πŸ’‰ Device Therapy πŸš€ show art Renal Nerves πŸ”₯ Blood Pressure πŸ’‰ Device Therapy πŸš€

Dr. Baliga's 'Podkasts for Curious Docs'

πŸ’‘ Renal Denervation: A New Era in Hypertension Care 🩺   Despite decades of effective medications, only ~25% of patients worldwide achieve blood pressure control. Non-adherence remains a huge barrier. πŸ“‰   This Nature Reviews Cardiology article (Fisher & Kirtane, Sept 2025) explores the journey of renal denervation (RDN) β€” from Smithwick’s sympathectomy in the 1950s to today’s FDA-approved radiofrequency πŸ”₯ and ultrasound πŸ”Š catheter systems.   βœ… Sham-controlled trials show RDN lowers BP by 5–10 mmHg, similar to one effective antihypertensive drug. βœ…...

info_outline
Diverticulitis πŸ“ŠπŸ”¬πŸ’Š: Patterns, Pitfalls, and Practice show art Diverticulitis πŸ“ŠπŸ”¬πŸ’Š: Patterns, Pitfalls, and Practice

Dr. Baliga's 'Podkasts for Curious Docs'

πŸ“˜ New Insights on Diverticulitis πŸ“ŠπŸ”¬πŸ’Š Did you know that while 1–4% of people with diverticulosis develop diverticulitis, it still accounts for ~200,000 hospitalizations annually in the US and >$6.3B in healthcare costs? πŸš‘πŸ’° βœ… CT scan remains the gold standard for diagnosis πŸ–ΌοΈ βœ… Observation & pain control are first-line for uncomplicated cases πŸ’Š βœ… Antibiotics reserved for high-risk groups (elderly, immunocompromised, pregnant, systemic illness) ⚠️ βœ… Surgery indicated for recurrent or complicated cases (fistula, stricture, perforation) βœ‚οΈ...

info_outline
Hypertension: Old Foe πŸ₯Š, Novel Therapies πŸ›‘οΈ, Brighter Outcomes 🌈 show art Hypertension: Old Foe πŸ₯Š, Novel Therapies πŸ›‘οΈ, Brighter Outcomes 🌈

Dr. Baliga's 'Podkasts for Curious Docs'

🚨 Hypertension remains the world’s #1 killer β€” yet fewer than 1 in 4 patients achieve control.   πŸ’Š Exciting innovations are reshaping the field: βœ”οΈ Aprocitentan (endothelin receptor antagonist) – first new class in decades βœ”οΈ siRNA (zilebesiran) – 6-monthly dosing, tackling adherence βœ”οΈ Aldosterone synthase inhibitors – overcoming β€œaldosterone escape” βœ”οΈ Non-steroidal MRAs & neprilysin inhibitors – precision targeting with broader benefits βœ”οΈ Single-pill & quadpill combos – simplifying therapy, boosting adherence   🌍 Together,...

info_outline
Dr RR Baliga's Philosophical Discourses: Ramanuja (India, 1017–1137 CE) – Vishishtadvaita Vedanta show art Dr RR Baliga's Philosophical Discourses: Ramanuja (India, 1017–1137 CE) – Vishishtadvaita Vedanta

Dr. Baliga's 'Podkasts for Curious Docs'

🌟 Ramanuja (1017–1137 CE), one of India’s greatest theologians, shaped Vishishtadvaita Vedanta (Qualified Non-Dualism). His vision of Atman (self) and Brahman (supreme reality), united through bhakti (devotion), transformed Hindu theology and inspired generations. πŸ•‰οΈπŸ“–   πŸ’‘ His commentaries on the Upanishads, Bhagavad Gita, and Brahma Sutras laid the foundation of Sri Vaishnavism and emphasized a path of devotion, grace, and liberation (moksha). ✨   πŸ™ A reminder for today’s healthcare providers and leaders: true service blends knowledge, humility, and...

info_outline
πŸ‘₯ Risk, Representation, Reality: Rethinking CVD Research for 2 Billion South Asian Lives show art πŸ‘₯ Risk, Representation, Reality: Rethinking CVD Research for 2 Billion South Asian Lives

Dr. Baliga's 'Podkasts for Curious Docs'

🧬 South Asians make up 25% of the worldβ€”yet just 3% of major cardiovascular trials. A new systematic review (310 RCTs, 1M+ participants) reveals stark underrepresentation, especially outside India. No South Asians in trials for heart failure, cardiac arrest, or valvular disease. πŸ“‰ The data gap is realβ€”and it’s limiting care.   πŸ” We need global trial designs that are inclusive, disaggregated, and powered for equity. Let’s change the research playbook. πŸ’‘   #CardioTrials #SouthAsianHealth #DiversityInResearch #PrecisionMedicine #GlobalHealth πŸŒπŸ«€πŸ“Š

info_outline
πŸ™οΈ Steps, Cities, Change: How Urban Design Boosts Activity πŸšΆβ€β™‚οΈπŸ“ˆ show art πŸ™οΈ Steps, Cities, Change: How Urban Design Boosts Activity πŸšΆβ€β™‚οΈπŸ“ˆ

Dr. Baliga's 'Podkasts for Curious Docs'

πŸšΆβ€β™€οΈπŸ“² New research alert! A massive natural experiment tracking 7,447 relocations across 1,609 US cities reveals that urban walkability directly boosts physical activity πŸ™οΈπŸ’ͺ   πŸ“ˆ Moving to more walkable cities increased daily steps by ~1,100 and doubled compliance with MVPA guidelines! 🎯 A powerful case for urban design as preventive medicine.   πŸ”— A must-read for public health advocates, city planners, and digital health innovators! #Walkability #UrbanHealth #DigitalEpidemiology #MVPA #SmartCities #BuiltEnvironment #PublicHealth πŸƒβ€β™‚οΈπŸŒ†

info_outline
ENaC βš™οΈ RAAS ⚑ Immunity 🧬:  The Gender Divide in Hypertension show art ENaC βš™οΈ RAAS ⚑ Immunity 🧬: The Gender Divide in Hypertension

Dr. Baliga's 'Podkasts for Curious Docs'

πŸ§‚ Salt sensitivity of blood pressure (SSBP) is an independent risk factor for CVD.   🚹🚺 Women are more salt-sensitive than men, especially after menopause. βš™οΈ Key drivers: RAAS, ENaC, natriuresis, and immune pathways. πŸ’‰ Estrogen protects, testosterone raises pressure, menopause tips the balance.   πŸ€ From Dahl’s rats to Conn’s syndrome, SSBP research shows why sex-specific, personalized therapy is the future of hypertension care.   πŸ”— Nature Reviews Cardiology

info_outline
Fatty Liver, Failing Heart, Future Risks πŸ”πŸ«€βš οΈ show art Fatty Liver, Failing Heart, Future Risks πŸ”πŸ«€βš οΈ

Dr. Baliga's 'Podkasts for Curious Docs'

Liver, Lipids, and the Left Ventricle πŸ©ΈπŸ«€πŸ§¬   The NEJM review reminds us that fatty liver isn’t just a liver problem. MASLD drives risk for heart disease, diabetes, kidney dysfunction, and even cancers. 🚨   Cardiovascular disease remains the leading cause of death in MASLDβ€”outpacing cirrhosis and cancer. πŸ«€πŸ’”   With new tools like FIB-4, VCTE, ELF, and promising drugs such as resmetirom and GLP-1/GIP agonists, we’re entering an era where treating the liver can protect the heart. πŸ’ŠπŸŒ±   #MASLD #LiverHeartConnection #NEJM #CardiometabolicHealth

info_outline
βš–οΈ Switch or Stay? DOACs vs Warfarin in Frail AF Patients show art βš–οΈ Switch or Stay? DOACs vs Warfarin in Frail AF Patients

Dr. Baliga's 'Podkasts for Curious Docs'

πŸ§“πŸ’Š The COMBINE-AF substudy offers important guidance for managing frail, elderly, VKA-experienced patients with atrial fibrillation. Switching to standard-dose DOACs reduced stroke/systemic embolism risk and cut intracranial & fatal bleeding πŸ§ πŸ›‘οΈ, but raised gastrointestinal bleeding rates πŸ½οΈπŸ©Έβ€”especially with certain agents. Sensitivity analyses show apixaban & edoxaban may offer a safer bleeding profile. These findings highlight the need for shared decision-making βš–οΈ and integrated ABC pathway care ❀️ to balance prevention, safety, and patient...

info_outline
 
More Episodes

πŸ’‘ Renal Denervation: A New Era in Hypertension Care 🩺

 

Despite decades of effective medications, only ~25% of patients worldwide achieve blood pressure control. Non-adherence remains a huge barrier. πŸ“‰

 

This Nature Reviews Cardiology article (Fisher & Kirtane, Sept 2025) explores the journey of renal denervation (RDN) β€” from Smithwick’s sympathectomy in the 1950s to today’s FDA-approved radiofrequency πŸ”₯ and ultrasound πŸ”Š catheter systems.

 

βœ… Sham-controlled trials show RDN lowers BP by 5–10 mmHg, similar to one effective antihypertensive drug.

βœ… Durable safety profile, up to 10 years in registries.

βœ… Best suited for resistant hypertension, drug intolerance, or pill fatigue.

βœ… Implementation requires multidisciplinary teams and shared decision-making. 🀝

 

πŸš€ Future: Expanding to underrepresented populations, CKD, elderly, and even beyond hypertension (AFib, sleep apnea, metabolic syndrome).

 

πŸ‘‰ A fascinating example of how history, technology, and evidence converge to reshape cardiovascular medicine.